Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 3

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 3
---
 sac tions,” “Security Ownership of Certain Beneficial Owners and Management,” and “Supplemental Information Regarding Participants in the Solicitation.” To the extent that the Company’s directors and executive officers ha ve acquired or disposed of securities holdings since the applicable “as of” date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in Ownership of Securities on Form 4 or Initial Sta tem ents of Beneficial Ownership of Securities on Form 3 filed with the SEC. These documents are or will be available free of charge at the SEC’s website at www.sec.gov.

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax is Delivering Superior Value for Stockholders 3 | Following Our Successful Pivot, Dynavax is Delivering for Stockholders • Management and the Board transformed Dynavax from a struggling biotech company into a powerful commercial - stage vaccine company with an industry - leading profitable vaccine, a promising pipeline, and a strong foundation for growth • Dynavax delivered 203% total return to stockholders over the last five years while vaccine peers returned 9% and the S&P Biotechnology Select Industry Index (XBI) declined 17% over the same period (as of 17 - Apr - 2025 definitive proxy filing) • HEPLISAV - B is now the market - leading hepatitis B vaccine with $268M of revenue in 2024 and 44% U.S. market share as of year - end 2024 • Dynavax drove a successful business development strategy during the pandemic establishing a global portfolio of CpG 1018 adjuvant commercial supply agreements supporting the development of COVID - 19 vaccines, which generated >$950M in net product revenue from 2020 to 2022 • The Board and Management apply a disciplined approach to capital allocation pursuing attractive internal and corporate development opportunities including our Phase II Shingles vaccine candidate, which has the potential to disrupt a $4.2B market • As a result of our successful efforts, Dynavax ended 2024 with a cash balance of $714 million, and is one of the few vaccine companies that has returned meaningful capital to stockholders 1 This is the Optimal Board to Drive our Value Creation Potential Deep Track’s Plan Threatens Growth and Puts